Copyright
©The Author(s) 2021.
World J Gastroenterol. Feb 21, 2021; 27(7): 609-623
Published online Feb 21, 2021. doi: 10.3748/wjg.v27.i7.609
Published online Feb 21, 2021. doi: 10.3748/wjg.v27.i7.609
Table 1 Participant demographics
Total (n = 145), mean ± SD (% of cohort) | NASH | NAFL | |
Total cohort (n) | 145 | 87 | 58 |
Sex (male) | 88 (60.7%) | 46 | 42a |
Age | 60.2 ± 13.1 | 60.9 ± 13.2 | 59 ± 12.9 |
BMI average | 28.8 ± 4.7 | 29.9 ± 4.4 | 27.1 ± 4.8c |
Normal BMI (≥ 18.5 ≤ 22.9) | 21.4 ± 1.6 (n = 17) | n = 6 | n = 12 |
Overweight (≥ 23.0 ≤ 27.9) | 25.6 ± 1.1 (n = 43) | n = 26 | n = 26 |
Obese (≥ 27.5) | 32.1 ± 3.2 (n = 82) | n = 55 | n = 20 |
Blood serum tests | |||
AST (IU/L) | 47.8 ± 27.5 | 56.4 ± 29.8 | 34.8 ± 17.1c |
ALT (IU/L) | 59.8 ± 49.3 | 71.3 ± 51.5 | 42.6 ± 41.4c |
GGT | 85.9 ± 78.4 | 97.8 ± 85.8 | 69.3 ± 62.9b |
Total bilirubin (mg/dL) | 0.86 ± 0.4 | 0.8 ± 0.3 | 0.9 ± 0.4 |
Platelets (× 104/μL) | 19.4 ± 7.3 | 19.9 ± 7.5 | 18.8 ± 7 |
HbA1C (%) | 6.5 ± 1.1 | 6.6 ± 1.0 | 6.5 ± 1.1 |
Fasting insulin (mU/mL) | 20 ± 14.2 | 20.6 ± 11.6 | 19 ± 17.4 |
Fasting blood glucose (mg/dL) | 124 ± 34.7 | 126.1 ± 32.5 | 120.8 ± 37.8 |
Albumin (g/dL) | 4.3 ± 0.5 | 4.3 ± 0.4 | 4.2 ± 0.5 |
Non-invasive test | |||
cT1 | 871 ± 102 (n = 143) | 907 ± 90 (n = 87) | 817 ± 96c (n = 56) |
MR liver fat | 11.4 ± 6.1 (n = 143) | 13.6 ± 5.8 (n = 87) | 8.1 ± 5.1c (n = 56) |
CAP | 294.3 ± 47.4 (n = 117) | 309.1 ± 37.1 (n = 74) | 268.9 ± 52.7c (n = 43) |
VCTE-LSM | 12.8 ± 9.5 (n = 117) | 13 ± 8.4 (n = 74) | 12.5 ± 11.1 (n = 43) |
MRE | 4.2 ± 1.7 (n = 144) | 4.3 ± 1.5 (n = 88) | 4.1 ± 1.9 (n = 56) |
SE | 9.3 ± 2.7 (n = 84) | 9.6 ± 2.4 (n = 50) | 8.8 ± 3.1 (n = 33) |
Reported pre-existing conditions | |||
Hypertensive | n = 71 | n = 45 | n = 26 |
Dyslipidaemic | n = 111 | n = 72 | n = 39 |
Reported as diabetic | n = 97 | n = 59 | n = 38 |
Table 2 Range of histology scores reported across the entire cohort
Histology scores from biopsy (n = 144) | ||||
Score | Total | NASH | NAFL | |
Steatosis (Brunt) | 0 | 13 | 0 | 13 |
1 | 74 | 36 | 37 | |
2 | 35 | 30 | 5 | |
3 | 21 | 20 | 1 | |
Lobular inflammation | 0 | 13 | 0 | 1 |
1 | 91 | 48 | 51 | |
2 | 35 | 35 | 9 | |
3 | 4 | 3 | 0 | |
Ballooning | 0 | 39 | 0 | 39 |
1 | 72 | 55 | 16 | |
2 | 32 | 31 | 1 | |
3 | 0 | 0 | 0 | |
Fibrosis (Kleiner) | 0 | 5 | 1 | 0 |
1 | 24 | 10 | 14 | |
2 | 27 | 16 | 11 | |
3 | 55 | 39 | 15 | |
4 | 31 | 19 | 12 | |
NAS | 0 | 0 | 0 | 0 |
1 | 5 | 0 | 5 | |
2 | 23 | 0 | 22 | |
3 | 26 | 0 | 26 | |
4 | 25 | 25 | 1 | |
5 | 37 | 35 | 2 | |
6 | 16 | 16 | 0 | |
7 | 8 | 8 | 0 | |
8 | 2 | 2 | 0 |
Table 3 Spearman's correlation coefficients for all variables
cT1, (n = 143) | MR liver fat (n = 143) | MRE (n = 144) | VCTE-LSM (n = 117) | CAP (n = 117) | 2D SWE (n = 84) | |
Fibrosis | 0.24, P < 0.01 | -0.25, P <0.01 | 0.75, P < 0.001 | 0.69, P < 0.001 | 0.05, P = 0.58 | 0.72, P < 0.001 |
Steatosis | 0.29, P < 0.001 | 0.70, P < 0.001 | -0.23, P < 0.01 | -0.09, P = 0.23 | 0.39, P < 0.001 | -0.07, P = 0.53 |
Lobular inflammation | 0.31, P < 0.001 | 0.28, P < 0.001 | 0.16, P < 0.01 | 0.15, P = 0.10 | 0.26, P < 0.01 | 0.16, P = 0.15 |
Ballooning | 0.39, P < 0.001 | 0.29, P < 0.001 | 0.32, P < 0.01 | 0.29, P < 0.01 | 0.33, P < 0.001 | 0.34, P < 0.001 |
NAS | 0.58, P < 0.001 | 0.64, P < 0.001 | 0.06, P = 0.44 | 0.13, P = 0.13 | 0.49, P < 0.001 | 0.16, P = 0.13 |
Table 4 Inter-rater variability between the three pathologists for each histology metric
Histological metric | Pathologists | Kappa weighted | Lower CI | Upper CI | ASE | P value | Overall inter-rater variability |
Steatosis | 1 vs 2 | 0.609 | 0.517 | 0.7 | 0.0467 | < 0.0001 | 0.584 |
1 vs 3 | 0.483 | 0.388 | 0.579 | 0.0489 | < 0.0001 | ||
2 vs 3 | 0.585 | 0.485 | 0.686 | 0.0513 | < 0.0001 | ||
Lobular inflammation | 1 vs 2 | 0.118 | 0.0631 | 0.173 | 0.0281 | < 0.0001 | 0.109 |
1 vs 3 | 0.0376 | 0.00574 | 0.0695 | 0.0163 | 0.02 | ||
2 vs 3 | 0.179 | 0.0699 | 0.288 | 0.0556 | 0.001 | ||
Ballooning | 1 vs 2 | 0.297 | 0.205 | 0.389 | 0..047 | < 0.0001 | 0.398 |
1 vs 3 | 0.459 | 0.344 | 0.573 | 0.0583 | < 0.0001 | ||
2 vs 3 | 0.27 | 0.18 | 0.36 | 0.0453 | < 0.0001 | ||
Fibrosis | 1 vs 2 | 0.719 | 0.65 | 0.788 | 0.0353 | < 0.0001 | 0.398 |
1 vs 3 | 0.571 | 0.496 | 0.647 | 0.0386 | < 0.0001 | ||
2 vs 3 | 0.597 | 0.521 | 0.672 | 0.0385 | < 0.0001 | ||
NAS | 1 vs 2 | 0.279 | 0.202 | 0.357 | 0.0398 | < 0.0001 | 0.421 |
1 vs 3 | 0.244 | 0.172 | 0.316 | 0.0366 | < 0.0001 | ||
2 vs 3 | 0.434 | 0.35 | 0.518 | 0.043 | < 0.0001 |
- Citation: Imajo K, Tetlow L, Dennis A, Shumbayawonda E, Mouchti S, Kendall TJ, Fryer E, Yamanaka S, Honda Y, Kessoku T, Ogawa Y, Yoneda M, Saito S, Kelly C, Kelly MD, Banerjee R, Nakajima A. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort. World J Gastroenterol 2021; 27(7): 609-623
- URL: https://www.wjgnet.com/1007-9327/full/v27/i7/609.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i7.609